We established a subcutaneous tumor mouse model using Hepa1‐6 cells and observed that administration of oxaliplatin had a pronounced effect on inhibiting tumor growth and led to notable upregulation of NLRP3 and IL‐1β. Here, IL1B is linked to neoplasm.